skip to main content

Osteoporosis Therapy — SCE Endocrinology MCQ

Instant feedback + full explanation. One question, done properly.

HardEndocrinologyOsteoporosis TherapySCE Endocrinology

A woman has received denosumab 60 mg every six months for five years. She now needs to stop; eGFR is 72 mL/min/1.73 m² and calcium is normal. Which plan best limits rebound vertebral fractures?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: CPlanned zoledronate infusion at six months with CTX-guided follow-up

C is correct. Denosumab must not be stopped or delayed without an antiresorptive exit plan. NOGG recommends zoledronate 5 mg IV six months after the last denosumab injection, with serum CTX guiding further treatment; if CTX is unavailable, a further zoledronate dose six months later can be considered. A drug holiday, delayed rescue or progressively prolonged dosing permits rebound turnover. Teriparatide alone after denosumab can worsen transient bone loss.

Reference: https://www.nogg.org.uk/full-guideline/section-6-pharmacological-treatment-options